Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:~  * Stage IIIB disease with malignant pleural effusion~ * Stage IV disease~ * Recurrent disease~* Squamous cell histology allowed~* Not eligible for curative treatment or treatment with bevacizumab~* Measurable disease according to RECIST~* Tumor (paraffin blocks or slides) must be available for correlative biomarker studies~* No uncontrolled brain metastases (or leptomeningeal disease)~  * Controlled brain metastases allowed~    * Able to receive appropriate therapeutic radiotherapy~   * Able to taper off all steroids without symptoms suggestive of increased intracranial pressure (nausea, vomiting, focal neurologic symptoms) for at least 7 days~PATIENT CHARACTERISTICS:~* ECOG (Eastern Cooperative Oncology Group) performance status 0-2~* ANC (absolute neutrophil count) ≥ 1.5 x 10\^9/L~* Platelets ≥ 100 x 10\^9/L~* Hemoglobin ≥ 9.0 g/L~* Total bilirubin ≤ 1.5 mg/dL~* AST (aspartate aminotransferase) and ALT (alanine aminotransferase) \< 2.5 times upper limit of normal~* Creatinine ≤ 1.5 mg/dL OR creatinine clearance \> 50 mg/mL~* No known HIV or hepatitis B or C~* Not pregnant~* Negative pregnancy test~* Thrombotic or embolic event within the past 6 months allowed, provided adequately controlled with therapeutic anticoagulation~* Hemoptysis allowed, provided it is not life threatening or requires palliative procedures (e.g., endobronchial therapy or radiotherapy)~* No cardiac disease, including any of the following:~  * NYHA (New York Heart Association) class III-IV congestive heart failure~ * Unstable angina (angina symptoms at rest)~ * New onset angina (began within the past 3 months)~ * Myocardial infarction within the past 6 months~* No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg despite optimal medical management~* No peripheral neuropathy ≥ grade 2~* No active clinically serious infection \> CTCAE grade 2~* No serious non-healing wound, ulcer, or bone fracture~* No significant traumatic injury within the past 4 weeks~* No evidence or history of bleeding diathesis or coagulopathy~* No prior malignancy, except for adequately treated basal cell skin cancer, carcinoma in situ of the cervix, or other cancer for which the patient has been disease-free for 2 years~  * Stage I (T1c) prostate cancer adequately treated 2 years prior to diagnosis of NSCLC allowed, however metastatic prostate cancer currently receiving hormonal therapy or chemotherapy is not allowed~* No significant psychiatric illness, in the opinion of the principal investigator, that would prevent adequate informed consent or render therapy unsafe~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Concurrent therapeutic anticoagulation, \> 325 mg acetylsalicylic acid, or chronic non-steroid anti-inflammatory drug use allowed~* At least 14 days since prior and no concurrent radiotherapy~* More than 4 weeks since prior major surgery or open biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (nab-paclitaxel, carboplatin) (Type: EXPERIMENTAL): Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).